CLINICAL CORNER

0

LACK OF ACTION FOR INFANT EYE EXAMS. Only 18% of parents who participated in the American Optometric Association’s (AOA) American Eye-Q® survey report taking their infant to an eye doctor for a comprehensive assessment before the child’s first birthday. The majority of parents said they were aware that lazy eye (61%) and crossed eyes (63%) can be detected in infants but less than one-third were aware that cancer, farsightedness, and nearsightedness may also be detected during an infant exam. The AOA recommends that a child’s first eye exam take place at six months of age. Unless problems are detected, the next exam should be at age three.


ANTI-INFLAMMATORY EFFECTS OF ALA ON CORNEAL EPITHELIAL CELLS. Systemic polyunsaturated fatty acids (PUFAs) have been shown to improve the symptoms of dry eye syndrome due to their anti-inflammatory effects. This study evaluated the in-vitro anti-inflammatory effects of PUFAs on human corneal epithelial (HCE) cells. It concluded that alpha-linolenic acid (ALA) may serve as a potent anti-inflammatory agent in ocular surface inflammation. The anti-inflammatory effects of ALA are comparable to those of corticosteroids.


ANTI-VEGF INJECTIONS ASSOCIATED WITH IOP ELEVATION. A study was conducted to investigate previously normotensive eyes experiencing sustained elevated intraocular pressure (IOP) in association with long-term intravitreal antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD). Researchers found serial injections of anti-VEGF agents may lead to persistent IOP elevations that require glaucoma therapy. They advised eyecare practitioners should be aware of this potential, as it can occur even if patients have tolerated multiple prior injections without IOP elevation.


THIAZOLIDINEDIONE MAY RAISE RISK OF MACULAR EDEMA. In a retrospective cohort study of 103,368 participants, researchers evaluated the short- and long-term risks of developing diabetic macular edema (DME) among users versus non-users of thiazolidinediones in patients with type 2 diabetes. The study concluded that treatment with a thiazolidinedione was associated with an increased risk of DME at both one-year and 10-year follow-up evaluations in type 2 diabetics. Aspirin use and angiotensin-converting enzyme inhibitor use were associated with a reduced risk of DME.

Share.

Leave A Reply